Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
UK stocks rallied on Thursday as signs of progress by US pharma giant Pfizer in developing a coronavirus vaccine rekindled hopes of an economic recovery and US employment data for June beat market expectations.
At the close the FTSE 100 benchmark was up 64 points or 1% to 6,222 while the FTSE 250 mid-cap index also gained 1% or 170 points to 17,359.
Associated British Food was one of the biggest FTSE 100 gainers, up 4.1% to £20.45 despite forecasting a sharp decline in Primark revenue after sales slipped 75% in the third quarter owing to store closures during the lockdown.
For the full year, the company expects strong progress in the group operating profit thanks to strong performances from its sugar, grocery, agriculture and ingredients businesses.
Shares in Meggitt climbed 6.2% to 324p even as it warned of a hit to first-half group revenue, which it expects to be 15% lower than in the same period a year earlier due to lower sales in both its civil aerospace and energy divisions.
The component supplier to the defence and aerospace sectors said that in the second quarter widespread lockdowns had a 'material impact' on its civil aerospace business.
Air Partner soared 7.8% to 90.8p on the news it had continued to perform 'significantly ahead' of budget in June and had seen a recovery in both its private jets and safety & security businesses following weakness earlier this year.
LondonMetric Property rose 3.2% to 218.6p on the news that it would increase its first-quarter dividend following high levels of rent collection in the quarter.
The company said that 95% of advance rental payments due up to 24 June, had been collected.
Lekoil bubbled 2.7% higher to 2.25p as it reported its subsidiary Lekoil Oil and Gas Investments had secured a US$3.5m prepayment facility agreement with Shell Western Supply.
Mitchells & Butlers added 1.4% to 194p as it reported a pre-tax loss of £121m in its half-year but said it had been 'encouraged' that sales levels have grown each week at its German business since it re-opened in May.
4D Pharma edged down 1.3% to 40.3p despite news that its phase 2 clinical trial of a drug to treat the respiratory symptoms associated with Covid-19 was now open to enrolment, with the dosing of the first patients expected shortly.
Packaging firm DS Smith folded 7.3% to 295p making it the worst performer in the FSTE 100 after it reported a 2% decline in revenue to £6.04 billion in its full-year results, due to reduced pricing and volumes in Europe.
The firm said it saw a 'relatively limited' impact on operating profit of approximately £15 million in the final two months of the year from the COVID-19 pandemic, but given the uncertain outlook it would not be reinstating dividends, disappointing investors.